Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C. (Q50554860)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 October 2011

Language	Label	Description	Also known as
English	Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C.	scientific article published on 12 October 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

Francisco Abad-Santos

8

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

Rosario López-Rodríguez

object named as

R Lopez-Rodriguez

1

0 references

author name string

M Trapero-Marugan

2

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

M J Borque

3

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

M Roman

4

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

A Hernandez-Bartolome

5

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

Y Rodriguez-Muñoz

6

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

S Martin-Vilchez

7

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

P Muñoz de Rueda

9

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

J R Vidal-Castiñeira

10

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

L Rodrigo

11

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

J Salmeron

12

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

R Moreno-Otero

13

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

P Sanz-Cameno

14

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

language of work or name

0 references

publication date

12 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

90

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

5

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

712-721

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Viruses and interferons

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Interferon signaling and treatment outcome in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

The human 2'-5'oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2'-5' instead of 3'-5' phosphodiester bond formation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Interaction between the 2'-5' oligoadenylate synthetase-like protein p59 OASL and the transcriptional repressor methyl CpG-binding protein 1

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

2',5'-Oligoadenylate synthetase-like gene highly induced by hepatitis C virus infection in human liver is inhibitory to viral replication in vitro

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Activation of 2'-5' oligoadenylate synthetase by single-stranded and double-stranded RNA aptamers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

The human 2',5'-oligoadenylate synthetase family: interferon-induced proteins with unique enzymatic properties

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Single nucleotide polymorphisms in genes for 2'-5'-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Induction of the human protein P56 by interferon, double-stranded RNA, or virus infection

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Distinct induction patterns and functions of two closely related interferon-inducible human genes, ISG54 and ISG56

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Coordinated Regulation and Widespread Cellular Expression of Interferon-Stimulated Genes (ISG) ISG-49, ISG-54, and ISG-56 in the Central Nervous System after Infection with Distinct Viruses

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

ISG56 is a negative-feedback regulator of virus-triggered signaling and cellular antiviral response

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Cloning and Functional Analysis of New Members of STAT Induced STAT Inhibitor (SSI) Family: SSI-2 and SSI-3

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Defective Hepatic Response to Interferon and Activation of Suppressor of Cytokine Signaling 3 in Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Structure and function of a new STAT-induced STAT inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

SNPStats: a web tool for the analysis of association studies.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Hepatitis C and liver transplantation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.189

21 January 2018

Identifiers

10.1038/CLPT.2011.189

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21993426

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50554860&oldid=1233688967"